Literature DB >> 6474098

Detection and quantification of the terminal C5b-9 complex of human complement by a sensitive enzyme-linked immunosorbent assay.

T E Mollnes, T Lea, M Harboe.   

Abstract

An enzyme-linked immunosorbent assay for detection and quantification of the terminal complexes (SC5b-9 and membrane attack complex) of human complement is described. We separate the complex from the native complement components, to use antibodies against the native components in a 'double-antibody sandwich' technique. It is thereby possible to detect the terminal complement complex in solution without the requirement of specific antibodies against the neoantigens. The results show that the assay is both sensitive and specific. Evidence is presented that a terminal complement complex occurs in a normal plasma pool. The terminal complement complex may be valuable for evaluating both the physiology and pathophysiology of the complement system in vivo.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6474098     DOI: 10.1111/j.1365-3083.1984.tb00989.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  7 in total

Review 1.  Review: assessment of complement activation in clinical immunology laboratories: time for reappraisal?

Authors:  M Peakman; G Senaldi; D Vergani
Journal:  J Clin Pathol       Date:  1989-10       Impact factor: 3.411

2.  Measurement of complement activation products in patients with chronic rheumatic diseases.

Authors:  G Auda; E R Holme; J E Davidson; A Zoma; J Veitch; K Whaley
Journal:  Rheumatol Int       Date:  1990       Impact factor: 2.631

3.  Effect of nephritic factor on C3 and on the terminal pathway of complement in vivo and in vitro.

Authors:  T E Mollnes; Y C Ng; D K Peters; T Lea; J Tschopp; M Harboe
Journal:  Clin Exp Immunol       Date:  1986-07       Impact factor: 4.330

4.  Artificial surface-induced inflammation relies on complement factor 5: proof from a deficient person.

Authors:  Grethe Bergseth; John D Lambris; Tom Eirik Mollnes; Knut Tore Lappegård
Journal:  Ann Thorac Surg       Date:  2011-02       Impact factor: 4.330

5.  Terminal complement complex in plasma from patients with systemic lupus erythematosus and other glomerular diseases.

Authors:  I Horigome; J Seino; K Sudo; Y Kinoshita; T Saito; K Yoshinaga
Journal:  Clin Exp Immunol       Date:  1987-11       Impact factor: 4.330

6.  Enhanced complement activation is part of the unfavourable cardiovascular risk profile in South Asians.

Authors:  M A Siezenga; P K Chandie Shaw; R N van der Geest; T E Mollnes; M R Daha; T J Rabelink; S P Berger
Journal:  Clin Exp Immunol       Date:  2009-07       Impact factor: 4.330

7.  In Vitro and In Vivo Biocompatibility Evaluation of Polyallylamine and Macromolecular Heparin Conjugates Modified Alginate Microbeads.

Authors:  Vijayaganapathy Vaithilingam; Bjørg Steinkjer; Liv Ryan; Rolf Larsson; Bernard Edward Tuch; Jose Oberholzer; Anne Mari Rokstad
Journal:  Sci Rep       Date:  2017-09-15       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.